Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

This post was originally published on this siteSTOCKHOLM, March 18, 2024 /PRNewswire/ — Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor…

Continue Reading

Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

This post was originally published on this siteSTOCKHOLM, March 18, 2024 /PRNewswire/ — Gabather AB (Nasdaq First North Growth Market: GABA) today reports that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor…

Continue Reading

Fundación Libertad y Desarrollo hosts in Guatemala a delegation from Freedom House to present the report “Freedom in the World 2024”

This post was originally published on this siteGUATEMALA CITY, March 16, 2024 /PRNewswire/ — Fundación Libertad y Desarrollo (Freedom and Development Foundation) played host to the event “Freedom in the World: What’s Happening in Central America?” for the unveiling of the “Freedom in the World 2024” report compiled by Freedom House….

Continue Reading